The drug, a combination of the former’s Zetia and the latter’s Zocor, is set to compete with the likes of AstraZeneca’s Crestor and Pfizer’s Lipitor in the market for cholesterol busters.
S-P and MSD confirmed that a pitch was on the cards but declined to comment further. It is understood an appointment is likely within two months.
The drug was approved by the Food and Drug Administration in the US, where it is marketed under the name Vytorin, just last week.
Marketing approval is currently being sought across the European Union under its mutual recognition procedure, following approval in Germany earlier this year.
The drug has been shown to be more effective than Lipitor in one trial, the results of which were presented at the annual meeting of the American College of Cardiology earlier this year.